Rapport Therapeutics CSO reports 8,500-share sale via 10b5-1 plan

Rhea-AI Filing Summary

Rapport Therapeutics Chief Scientific Officer David Bredt reported sales of common stock under a Rule 10b5-1 plan adopted December 12, 2024. On 08/15/2025 he sold 8,300 shares at a weighted-average price of $14.9769 (trade prices ranged $14.65–$15.50) and sold 200 shares at a weighted-average price of $15.79 (trade prices ranged $15.74–$15.84). The filings show beneficial ownership following those transactions of 426,842 and 426,642 shares, respectively. The Form 4 was signed by attorney-in-fact Troy Ignelzi on 08/18/2025.

Positive

• Sales disclosed as executed under a Rule 10b5-1 plan, indicating pre-arranged trading rather than opportunistic timing
• Detailed price disclosure with weighted-average prices and ranges, plus an undertaking to provide per-price allocation on request
• Form 4 properly signed by attorney-in-fact (Troy Ignelzi) with a clear date

Negative

• Insider sold a total of 8,500 shares on 08/15/2025, reducing beneficial ownership to reported levels of 426,842 and 426,642 shares
• No information on purpose of sales is provided in the filing beyond the 10b5-1 plan statement

Insights

Financial Analyst

TL;DR: Insider executed routine sales under a standing 10b5-1 plan; disclosed weighted-average prices and post-sale holdings.

The transactions are presented as planned disposals pursuant to a Rule 10b5-1 trading plan adopted December 12, 2024, which indicates pre-arranged sales rather than ad-hoc transactions. Total reported shares sold on 08/15/2025 equal 8,500 shares at weighted-average prices shown in the filing, producing reported beneficial holdings of 426,842 and 426,642 after each line item. There is no derivative activity reported on this Form 4. For investors this is a clear, routine disclosure of insider liquidity rather than an operational update.

Corporate Governance Expert

TL;DR: Disclosure follows Section 16 rules and cites a valid 10b5-1 plan; signature by attorney-in-fact is included.

The Form 4 explicitly states the sales were effected pursuant to a Rule 10b5-1 plan and provides weighted-average price ranges and an undertaking to provide per-price allocation on request, which supports transparency. The filing includes an attorney-in-fact signature dated 08/18/2025. There are no amendments or derivative disclosures on this filing. This appears to be a compliant insider transaction report rather than a governance exception or corrective filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bredt David

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S(1)		8,300	D	$14.9769(2)	426,842	D
Common Stock	08/15/2025		S(1)		200	D	$15.79(3)	426,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.74 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did RAPP Chief Scientific Officer David Bredt sell on 08/15/2025?

He sold 8,300 shares at a weighted-average price of $14.9769 (prices ranged $14.65–$15.50) and 200 shares at a weighted-average price of $15.79 (prices ranged $15.74–$15.84).

Were the transactions by the RAPP insider part of a 10b5-1 plan?

Yes. The Form 4 states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

How many shares did David Bredt beneficially own after the reported sales?

The filing reports beneficial ownership of 426,842 shares after the first reported sale and 426,642 shares after the second line item.

Does the Form 4 show any derivative securities for David Bredt?

No. Table II for derivative securities shows no transactions or holdings reported in this filing.

Who signed the Form 4 for the reporting person?

The Form 4 is signed by attorney-in-fact Troy Ignelzi with a signature date of 08/18/2025.